Announcements Trials
Browse Landscape

Phase

Phase 4 2Phase 2 2

Status

Completed 2Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2Other neoplasm 1Lymphoid 1

Conditions

Precancerous Conditions 1Mycosis Fungoides 1Lymphoma, T-Cell, Cutaneous 1Keratosis, Actinic 1Dermatitis, Contact 1Carcinoma, Basal Cell 1

Interventions

Cyclophosphamide 741Cisplatin 688Gemcitabine 641Bevacizumab 616Carboplatin 605Paclitaxel 601Docetaxel 565Radiotherapy 536Fluorouracil 405Oxaliplatin 387Rituximab 369Doxorubicin 361Capecitabine 342Filgrastim 333Etoposide 330Dexamethasone 312Irinotecan 309pembrolizumab 282Leucovorin 274Cetuximab 268Cytarabine 242Erlotinib Hydrochloride 231Nivolumab 228Prednisone 227Trastuzumab 225Vincristine 221Bortezomib 221Methotrexate 207Pemetrexed 199fludarabine phosphate 195

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Completed × Triamcinolone × Clear all
NCT03380026 2021-11-24

MIDAS

Rochester Skin Lymphoma Medical Group, PLLC

Phase 2 Completed
28 enrolled 8 charts
DermatologicLymphoid

Dermatitis, Contact, Mycosis Fungoides, Lymphoma, T-Cell, Cutaneous

NCT00021294 2018-09-11

Eflornithine With or Without Triamcinolone in Preventing Nonmelanoma Skin Cancer in Patients With Actinic Keratosis

University of Arizona

Phase 2 Completed
DermatologicOther neoplasm

Carcinoma, Basal Cell, Precancerous Conditions, Keratosis, Actinic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡